Herpes zoster nursing reference: assessment, interventions, and NCLEX review

Herpes zoster — commonly called shingles — is the reactivation of varicella-zoster virus (VZV) that has remained dormant in the dorsal root ganglia since a prior chickenpox infection. The virus never fully clears the body; it retreats to sensory nerve cell bodies and waits. When the immune system weakens — through aging, immunosuppressive therapy, or physiologic stress — viral replication resumes and the virus travels back down the nerve axon to the skin, producing a painful dermatomal rash that is the hallmark of the disease. Roughly one in three Americans will develop herpes zoster during their lifetime, with risk rising sharply after age 50. For nursing students, shingles is a high-yield topic that spans multiple exam domains at once: recognizing the correct isolation tier, understanding the 72-hour antiviral window, distinguishing the feared complications, and knowing when to urgently escalate.

At-a-glance quick reference

Pathophysiology

VZV latency

Herpes zoster begins with an infection that happened years or decades earlier. During primary varicella (chickenpox), VZV enters the body through the respiratory mucosa and undergoes a primary then secondary viremia that seeds the skin — producing the characteristic disseminated vesicular rash — and simultaneously travels retrograde along sensory nerve axons to the dorsal root ganglia. There the virus inserts its genome into the host cell nucleus and enters a state of latency, producing no viral proteins and no symptoms while the host’s cellular immune system keeps it suppressed.

Latency is not permanent. As we age, cell-mediated immunity to VZV gradually declines. The same process occurs faster and more dramatically in patients on high-dose corticosteroids, chemotherapy, biologic agents (especially TNF inhibitors), or with HIV/AIDS. Severe physical or emotional stress, malnutrition, and sleep deprivation can also contribute. When VZV-specific T-cell surveillance falls below a threshold, the virus begins replicating in the ganglion cell body — causing the intense neuronal inflammation that produces the prodromal pain — then travels anterograde down the sensory nerve to the skin served by that nerve, where it replicates further and erupts through the epidermis as vesicles.

Dermatomal distribution

Because VZV reactivates in a single sensory ganglion, the rash follows that ganglion’s dermatome: a unilateral, band-like distribution that wraps around one side of the body without crossing the midline. The thoracic dermatomes (T3–T12) are affected in approximately 53% of cases, making a “belt-like” torso rash the most common presentation. Cervical dermatomes account for about 20%, trigeminal (facial) for 15% — with the ophthalmic branch (V1) being particularly dangerous — and lumbosacral for approximately 11%. The strict unilateral, dermatomal character of the rash is the key feature distinguishing herpes zoster from other vesicular eruptions. Bilateral rash or rash crossing the midline should prompt consideration of disseminated disease, especially in immunocompromised patients.

Viral shedding and contagiousness

Active vesicles contain live VZV and are infectious to individuals without prior varicella immunity or vaccination. The period of infectivity begins when vesicles appear and ends when all lesions have dried and crusted — typically 7–10 days after rash onset. Crusted lesions do not shed virus and are not infectious. Importantly, a person cannot catch shingles from someone with shingles; susceptible contacts exposed to VZV from zoster lesions develop primary varicella (chickenpox), not zoster.

Clinical presentation and staging

Herpes zoster follows a predictable sequence of three stages. Understanding the timeline and features of each stage guides both clinical management decisions and patient education.

Prodrome phase

The prodromal phase is the most diagnostically deceptive stage. Pain, burning, or hypersensitivity appears in the affected dermatome 2–3 days before any skin lesions are visible. The pain can be severe enough to mimic other conditions — thoracic prodromal pain is sometimes mistaken for myocardial infarction or pleurisy; lumbar prodromal pain may suggest renal colic or appendicitis. At this stage there is nothing to see on the skin, so the diagnosis rests entirely on clinical suspicion, particularly in older or immunocompromised patients who present with unexplained unilateral dermatomal pain.

Active (eruptive) phase

Within 2–3 days of prodromal symptoms, the rash erupts. The classic progression runs: erythematous macules → papules → clear fluid-filled vesicles → cloudy pustules → crusting. Vesicles typically appear in clusters on an erythematous base — described as “dewdrops on a rose petal” — strictly confined to the affected dermatome and limited to one side of the body. Pain during this phase is often severe, described as burning, stabbing, or electric shock-like. Allodynia — pain elicited by light touch that would not normally cause pain — is common and can be profound. In immunocompetent adults, new lesion formation typically ceases within 4 days; in immunocompromised patients, new lesions may continue appearing for weeks.

Crusting phase

Lesions progress to crusting over the next 7–10 days. Complete crusting marks the end of the infectious period. Pain typically diminishes as lesions resolve, though the rate of resolution varies widely. The skin may heal with temporary hyperpigmentation or, in severe cases, permanent scarring. When pain persists beyond the healing period — arbitrarily defined as more than 90 days after rash onset — the diagnosis is postherpetic neuralgia.

Complications

Postherpetic neuralgia

PHN is the most common and most feared complication of herpes zoster, affecting approximately 10–15% of all shingles patients but rising to 25–50% of patients over age 70. The defining feature is pain persisting beyond 90 days after rash onset — by this definition, the rash has healed but the nerve damage from the viral infection has left behind a state of chronic neuropathic sensitization. The pain is characteristically burning, shooting, or stabbing, often accompanied by severe allodynia in which even light clothing touching the skin causes agonizing discomfort. Strong independent risk factors for PHN include age over 60, severe pain or sensory loss during the acute phase, prodromal pain before rash onset, ophthalmic branch involvement, and delayed antiviral treatment. This is precisely why starting antivirals within 72 hours of rash onset matters: earlier treatment reduces viral load and thus reduces the degree of sensory nerve damage that drives PHN.

Herpes zoster ophthalmicus

HZO results from reactivation in the ophthalmic branch (V1) of the trigeminal nerve and accounts for 10–25% of all herpes zoster cases. The rash involves the forehead and upper eyelid distribution. A critical clinical sign is the Hutchinson sign — vesicles on the tip or side of the nose, which indicates involvement of the nasociliary branch and correlates strongly with ocular involvement. Without prompt treatment, HZO can cause keratitis, uveitis, optic neuritis, and permanent vision loss. Any patient with a V1 distribution rash requires urgent ophthalmology referral and aggressive antiviral therapy regardless of whether eye symptoms are present yet.

Ramsay Hunt syndrome

Ramsay Hunt syndrome (herpes zoster oticus) results from reactivation in the geniculate ganglion of the facial nerve (CN VII), with spread to the vestibulocochlear nerve (CN VIII). The clinical triad is: painful vesicles in the external ear canal or on the palate/tonsillar pillars, ipsilateral facial nerve palsy (drooping, inability to close the eye, loss of forehead wrinkling), and vestibular-cochlear dysfunction (sensorineural hearing loss, tinnitus, vertigo). Facial nerve recovery is variable — approximately 75% of patients recover full facial function with prompt combined antiviral and corticosteroid treatment, but recovery may be incomplete, particularly in older patients.

Nursing assessment

A thorough herpes zoster assessment covers four domains: pain, skin, neurological, and immune history.

Pain assessment

Zoster pain is neuropathic in character and typically severe. Document pain using a 0–10 numeric scale or appropriate scale for the patient’s cognitive level. Assess character (burning, shooting, stabbing, electric), location (which dermatome, bilateral or unilateral), and the presence of allodynia — ask the patient whether light touch or clothing contact triggers pain, as this indicates significant nerve sensitization. Note the temporal pattern: pain that began before the rash appeared confirms the classic prodromal sequence and provides useful prognostic information, since severe prodromal pain is a risk factor for PHN.

Skin assessment

Assess the distribution, stage, and coverage of all lesions. Note: Is the rash strictly unilateral? Does it respect the midline? Which dermatome(s) is involved? Are lesions in a single stage (expected for zoster) or multiple stages simultaneously (more typical of varicella)? Count the number of lesions — more than 20 outside the primary dermatome meets criteria for disseminated disease and mandates a change in isolation precautions and escalation of antiviral therapy. Inspect for signs of secondary bacterial superinfection: increasing erythema, warmth, purulence, or expanding cellulitis around lesion borders.

Neurological assessment

Target neurological assessment to the involved nerve territory. For facial/cranial involvement, assess: facial symmetry at rest and with voluntary movement (smile, raise eyebrows, close eyes forcefully), visual acuity and pupillary response for suspected HZO, hearing and balance for Ramsay Hunt syndrome. Document any new deficits at baseline and trend them each shift.

Immunosuppression history

Establish the patient’s immune status. Active zoster in a young immunocompetent adult warrants a lower-key clinical approach; zoster in a patient on chemotherapy, biologic agents, or with known HIV warrants more aggressive management, including consideration of IV acyclovir. Ask about: current or recent corticosteroid use (including inhalers at high dose), chemotherapy or radiation therapy, solid organ or bone marrow transplant, HIV status and most recent CD4 count, and biologic or immunomodulatory drug use.

Nursing interventions

Isolation precautions

The correct isolation tier for herpes zoster depends on two variables: the extent of disease and the immune status of the patient.

• Localized herpes zoster in an immunocompetent patient: Contact precautions are required (gown and gloves for any patient contact or contact with the environment). Standard precautions also apply. A private room is ideal but not always required if the roommate is immune to VZV. Airborne precautions are NOT required for localized disease in immunocompetent patients — a key distinction tested on NCLEX.
• Disseminated herpes zoster OR any herpes zoster in an immunocompromised patient: Both airborne AND contact precautions are required. The immunocompromised host sheds virus more extensively, including from oral and respiratory secretions, increasing aerosolization risk. A negative-pressure private room and N95 respirator are required until all lesions are fully crusted.
• Duration: All precautions continue until every lesion has dried and crusted completely. Partially crusted lesions should not be considered safe — any open vesicle represents a shedding source.

Healthcare workers without VZV immunity (unvaccinated, no prior chickenpox history) should not care for patients with active herpes zoster. Pregnant staff without documented VZV immunity should be reassigned.

For comparison, recall from varicella (chickenpox) nursing that primary varicella always requires airborne plus contact precautions in all patients, regardless of immune status — because varicella involves respiratory shedding from the outset. Herpes zoster requires airborne precautions only under the specific circumstances above.

Antiviral therapy

Antiviral treatment must begin within 72 hours of rash onset to achieve maximum clinical benefit. The 72-hour clock starts when the first vesicle appears — not when prodromal symptoms begin. Early treatment reduces viral replication, limits the degree of sensory nerve injury, accelerates lesion healing, reduces new lesion formation, and most importantly reduces the incidence and severity of postherpetic neuralgia. Antivirals are less effective when started after 72 hours, though they may still benefit patients with ongoing new lesion formation, severe disease, or ophthalmic involvement regardless of timing.

See the medications table below for specific agents, doses, and durations.

Pain management

Zoster pain is severe and neuropathic — standard analgesics alone are frequently insufficient. Nursing priorities include:

• Scheduled dosing: Analgesics given on a fixed schedule (not PRN) provide better steady-state pain control than reactive dosing. This is especially important in the acute phase when pain is most severe.
• Gabapentinoids: Gabapentin and pregabalin are first-line agents for neuropathic pain management, particularly for PHN. They work by binding to the α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release in sensitized dorsal horn neurons. In the acute phase, gabapentin may reduce both acute pain and the subsequent risk of PHN.
• Tricyclic antidepressants (TCAs): Nortriptyline or amitriptyline are evidence-based options for neuropathic pain, with nortriptyline preferred in older adults due to a better tolerability profile. TCAs modulate pain through norepinephrine reuptake inhibition in descending pain pathways.
• Topical agents: 5% lidocaine patches applied to the area of maximal pain provide localized relief for PHN without systemic absorption. Topical capsaicin (0.025–0.075% cream or the high-concentration 8% patch applied in clinic) depletes substance P from nerve endings and reduces pain with regular use. Cooling compresses in the acute phase can soothe allodynia.
• Opioids: Reserved for severe pain inadequately controlled by the above. Short courses are occasionally appropriate in the acute phase.

Wound care

Keep lesions clean and dry. Gentle cleansing with mild soap and water, followed by complete drying, reduces the risk of secondary bacterial superinfection. Loose-fitting clothing minimizes friction-related allodynia. If dressings are needed to cover oozing lesions or prevent environmental contamination, use non-adherent, non-occlusive materials — occlusive dressings delay drying and prolong the infectious period. Do not apply topical antibiotic ointments unless a secondary bacterial infection is confirmed, as routine application can macerate the skin and delay crusting.

Patient education

Patients need clear, specific teaching about contagiousness, medication timing, and warning signs. Key points:

• Who to avoid: Until all lesions are crusted, avoid close contact with pregnant women without proven varicella immunity, immunocompromised individuals, and infants under one month of age. These populations risk primary varicella infection from contact with zoster lesions.
• Keep lesions covered: Clothing or a non-stick dressing over the rash reduces environmental contamination risk.
• Antiviral adherence: Completing the full antiviral course even if symptoms improve is critical to reduce PHN risk.
• PHN warning signs: Teach patients that if pain persists weeks after the rash has healed, they should seek follow-up — PHN is treatable but requires early intervention.
• Return precautions: Fever, spreading redness, increasing pain after initial improvement, facial weakness, ear pain, or any change in vision should prompt immediate return.

Antiviral and analgesic medications

All antivirals are most effective when started within 72 hours of rash onset. Renal function must be checked before initiation — all three oral agents and IV acyclovir require dose adjustment in chronic kidney disease.

Vaccine and prevention

Shingrix (recombinant zoster vaccine)

Shingrix (RZV) is the current standard for herpes zoster prevention, having replaced the older live zoster vaccine (Zostavax) which is no longer available in the United States as of November 2020. Unlike Zostavax, Shingrix is a recombinant, adjuvanted, non-live vaccine — making it safe for use in immunocompromised patients.

CDC recommendations:

• Adults aged 50 years and older — two-dose series regardless of prior varicella infection or vaccination history, or prior Zostavax vaccination
• Adults aged 19 years and older who are immunocompromised** — two-dose series

Dosing schedule:

• Dose 1: administer at the selected clinic visit
• Dose 2: 2–6 months after dose 1 in immunocompetent adults; 1–2 months after dose 1 may be used in immunocompromised patients requiring faster protection

Efficacy data (CDC):

• Adults 50–69: ~97% effective in preventing shingles
• Adults 70+: ~91% effective in preventing shingles
• Prevention of PHN in adults 50+: ~91% effective
• Prevention of PHN in adults 70+: ~89% effective
• Immunocompromised populations: 68–91% effective depending on underlying condition

Contraindications:

• Current active shingles (wait until resolved)
• Severe allergic reaction to a prior dose or to any vaccine component
• Pregnancy (defer until after delivery)

Nursing implications:

• Shingrix is given intramuscularly, preferably in the deltoid
• Common adverse effects are local (injection site pain, redness, swelling) and systemic (fatigue, myalgia, headache, shivering, fever, GI symptoms) — these reflect the adjuvant-driven immune response and are more pronounced than with most adult vaccines; counsel patients to expect them
• Adverse effects typically resolve within 2–3 days
• Patients previously vaccinated with Zostavax should still receive a 2-dose Shingrix series
• Minor acute illness does not contraindicate vaccination; moderate-to-severe illness requires deferral until recovery

NCLEX review questions

Related resources

This article is part of the infectious disease cluster. Related reference pages that pair well with this content:

• Varicella (chickenpox) nursing care — primary VZV infection, airborne + contact precautions, Reye’s syndrome, VariZIG
• Sepsis nursing reference — for disseminated HZV with systemic inflammatory response
• Wound assessment — systematic skin assessment principles applicable to vesicular lesions
• Nursing lab values cheat sheet — reference values for monitoring renal function before antiviral dosing
• Pharmacology nursing guide — antiviral and neuropathic pain drug mechanisms